Regulatory agencies, particularly the European Medicines Agency (EMA), have intensified their focus on reproductive and developmental safety monitoring, reflecting growing recognition that both maternal and paternal exposures may carry meaningful risks for offspring health.
While maternal linkage is relatively well established in certain European countries, paternal linkage remains rare despite growing biological evidence supporting its relevance to offspring health outcomes. This piece highlights the value of scientific, regulatory, and infrastructural efforts to enable the use of father-child linked data within the broader field of parentchild linkage in post-authorization safety studies (PASS) in the EU and what it will take to get there.
Fill out the form to the right to read the full perspective.
Fill out the form to read the full perspective
"*" indicates required fields